Company news

Biohaven Ltd. news in 2024

Biohaven Ltd.'s news releases, calls and decks from 2024, newest first.

View company

Biohaven Reports Positive Phase 1 Degrader Data, Achieving Deep Targeted IgG Reductions in the Lowest Subcutaneous Dose Tested, Announces NDA Submission for Troriluzole in SCA and Provides Other Key Program Updates

December 17, 2024

Biohaven Presents New Data with BHV-7000 Once-Daily Extended-Release Formulation Demonstrating Excellent Safety Profile and Nonclinical Data Updates at American Epilepsy Society 2024 Annual Meeting

December 9, 2024

Biohaven Provides Update on Taldefgrobep Alfa Development Program for Spinal Muscular Atrophy and Obesity

November 26, 2024

Biohaven Reports Third Quarter 2024 Financial Results and Recent Business Developments

November 13, 2024

Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters Option to Purchase Additional Shares

October 3, 2024

Biohaven Announces Pricing of $250 Million Public Offering of Common Shares

October 2, 2024

Biohaven Announces Conference Call to Discuss Topline Pivotal Study Results in Spinocerebellar Ataxia

September 23, 2024

Decks in 2024